16:45 , Sep 7, 2018 |  BC Week In Review  |  Clinical News

Bifunctional agonist could treat pain, opioid dependency

A team from Astraea Therapeutics LLC (Mountain View, Calif.) and Wake Forest Baptist Medical Center developed a bifunctional agonist targeting two opioid receptors that could treat pain without opioid-related side effects and reverse opioid dependency....
18:02 , Aug 29, 2018 |  BC Extra  |  Preclinical News

Bifunctional agonist could treat pain, opioid dependency

A team from Astraea Therapeutics LLC (Mountain View, Calif.) and Wake Forest Baptist Medical Center developed a bifunctional agonist targeting two opioid receptors that could treat pain without opioid-related side effects and reverse opioid dependency....
06:11 , Aug 10, 2018 |  BC Week In Review  |  Company News

BlackThorn licenses Yale's neuroimaging tech

Neurobehavioral disorder company BlackThorn Therapeutics Inc. (San Francisco, Calif.) exclusively licensed neuroimaging technology from Yale University School of Medicine designed to link gene expression patterns with behavioral circuits in the brain. Yale has dubbed the...
23:38 , Aug 6, 2018 |  BC Extra  |  Company News

BlackThorn licenses Yale's neuroimaging drug discovery tech

Neurobehavioral disorder company BlackThorn Therapeutics Inc. (San Francisco, Calif.) exclusively licensed neuroimaging technology from Yale University School of Medicine designed to link gene expression patterns with behavioral circuits in the brain. Yale has dubbed the...
19:19 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

BlackThorn brings KOR antagonist into clinic

BlackThorn Therapeutics Inc. (San Francisco, Calif.) began a Phase I trial evaluating up to seven single and multiple ascending doses of BTRX-335140 to assess dose exposure and safety in about 90 healthy volunteers. The company...
18:09 , May 15, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Spinal cord injury (SCI) Cell culture and mouse studies suggest antagonizing OPRL1 alone or in combination with inhibiting its downstream effector RTN4R could help treat SCI. In primary mouse cortical neurons subjected to scrape...
20:48 , Jul 28, 2017 |  BioCentury  |  Product Development

Circuit logic

BlackThorn Therapeutics Inc. has begun the first of a series of studies that will test whether it can solve a tough problem in neurological drug development: the tendency of heterogeneity among patients with the same...
06:32 , Jul 28, 2017 |  BC Week In Review  |  Clinical News

BlackThorn begins Phase IIa of BTRX-246040 for MDD

BlackThorn Therapeutics Inc. (South San Francisco, Calif.) began a double-blind, placebo-controlled, U.S. Phase IIa trial to evaluate BTRX-246040 for 8 weeks in about 100 patients with major depressive disorder (MDD) with or without anhedonia. Patients...
07:00 , Oct 20, 2016 |  BC Extra  |  Financial News

Neuroscience newco BlackThorn raises $40M

Neurobehavioral newco BlackThorn Therapeutics Inc. (South San Francisco, Calif.) raised $40 million in a series A round led by Arch Venture Partners. The Johnson & Johnson Innovation-JJDC venture arm of Johnson & Johnson (NYSE:JNJ), Altitude...
08:00 , Dec 4, 2014 |  BC Innovations  |  Cover Story

GPCRs' grand plans

In a move to expand tenfold the number of known 3D structures of the highly druggable class of GPCRs, Amgen Inc. , Ono Pharmaceutical Co. Ltd. and Sanofi have teamed up with three academic organizations...